There are a whole host of reasons to invest in healthcare stocks over the long term. The United States has an aging population.

The overall stock market has been reeling over the last week or so. The S&P 500 index and NASDAQ have fallen by 4% and 6%, respectively, since July 16 due to uncertainty regarding the future of artificial intelligence.

Thermo Fisher Scientific is a top dividend growth stock with a complex post-pandemic situation. Recent earnings show promising growth in key segments, despite a high valuation. Strategic investments in R&D and acquisitions position TMO for continued long-term success.

Given the expanding size of the nanotechnology industry, buying nanotechnology stocks with a very low-risk profile is possible. Electronics is one of the most important sectors that applies nanotechnology.

Thermo Fisher Scientific is finally starting to show signs of growth after getting through the headwind of declining covid-related business. Growth sources include increased business in China, completion of the Olink deal, and an increase in the number of clinical trials. Financial model updates and valuation analysis suggest the stock is currently priced at fair value, making it a Hold for now.

The year-over-year decline in Thermo Fisher's (TMO) Life Science Solutions and Laboratory Products and Biopharma Services revenues disappoints. However, margins expand in the second quarter.

The headline numbers for Thermo Fisher (TMO) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Thermo Fisher Scientific (TMO) reported better second-quarter earnings than analysts had expected Wednesday, and also raised its projections for the full fiscal year.

Thermo Fisher Scientific (TMO) came out with quarterly earnings of $5.37 per share, beating the Zacks Consensus Estimate of $5.13 per share. This compares to earnings of $5.15 per share a year ago.

Thermo Fisher on Wednesday raised its annual profit outlook and posted a better-than-expected second-quarter profit, banking on improved demand for its tools and services used in clinical trials.

Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.

Nanotech stocks remain at the forefront of every tech-savvy investor's portfolio, considering the predicted worldwide nanotechnology market size in 2024 is $91.18 billion. Analysts project market size will reach $332.73 billion by 2032, with a CAGR of 17.6%.